Showing results (2361-2370 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 13, 2010
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor modelsAndries M Bergman, Auke D Adema, Jan Balzarini, et al.
Investigational New Drugs|December 25, 2009
Preclinical investigation of tolerance and antitumour activity of new fluorodeoxyglucose-coupled chlorambucil alkylating agentsElisabeth Miot-Noirault, Bastien Reux, Eric Debiton, et al.
Investigational New Drugs|January 23, 2010
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)Hai T Tran, Ralph G Zinner, George R Blumenschein, et al.
Investigational New Drugs|March 17, 2010
Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NOSteven Hutchens, Yefim Manevich, Lin He, et al.
Investigational New Drugs|March 19, 2010
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancerSung Yong Oh, Young-Tae Ju, Sang-Kyung Choi, et al.
Investigational New Drugs|May 5, 2018
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinomaArthur Lui, Karen Mulder, Christine Brezden-Masley, et al.
Investigational New Drugs|April 19, 2018
Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in JapanHiroki Nakayama, Katsura Tsukamoto
Investigational New Drugs|May 27, 2009
MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cellsMirna Golemovic, Alfonso Quintás-Cardama, Taghi Manshouri, et al.
Investigational New Drugs|May 14, 2009
Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activitySatoki Nakamura, Mitsuji Yamashita, Daisuke Yokota, et al.
Investigational New Drugs|February 25, 2009
Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out miceJ H Beumer, N E Franke, R Tolboom, et al.
Pageof 372